{
    "clinical_study": {
        "@rank": "11615", 
        "arm_group": [
            {
                "arm_group_label": "Prostaglandin Analog vs Timolol", 
                "arm_group_type": "Experimental", 
                "description": "In this group, with thyroid eye disease and increased intraocular pressure in both eyes, prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye. Timolol 0.5% eye drop will be administered topically in second, control eye, two times a day."
            }, 
            {
                "arm_group_label": "Prostaglandin Analog", 
                "arm_group_type": "Experimental", 
                "description": "In this group, with thyroid eye disease and increased intraocular pressure in only one eye Prostaglandin Analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one, affected eye."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the potential secondary beneficial effect of\n      prostaglandin analogues (PA) treatment  in thyroid eye disease (TED) patients. This study\n      aims to determine if PA would change the course of  the orbitopathy in TED patients by\n      altering the progression of the common features of TED, including fatty hypertrophy,\n      proptosis, eyelid retraction and optic nerve compression. The eyes with thyroid eye disease\n      and elevated intraocular pressure will be randomised to the PA treatment and the other eye\n      will serve as a control eye and will be treated with Timolol."
        }, 
        "brief_title": "The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Thyroid Eye Disease", 
            "Ocular Hypertension", 
            "Glaucoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Eye Diseases", 
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension", 
                "Thyroid Diseases", 
                "Graves Ophthalmopathy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  mild or moderate to severe thyroid eye disease in one or both eyes\n\n          -  age > 18 years\n\n          -  informed consent\n\n          -  intraocular pressure > 21 mmHg or glaucoma suspect or glaucoma diagnosed in one or\n             both eyes\n\n          -  not on current prostaglandin analog intraocular pressure lowering therapy\n\n        Exclusion Criteria:\n\n          -  sight threatening thyroid eye disease\n\n          -  children < 18 years old\n\n          -  patients that are not compliant with treatment or follow-up\n\n          -  patients already on prostaglandin analog treatment\n\n          -  patients that undergo cosmetic periocular procedures during the study will be\n             excluded from further follow up\n\n          -  patients that cannot tolerate prostaglandin analog treatment.\n\n          -  patients with bilateral thyroid eye disease and elevated intraocular pressures that\n             cannot tolerate treatment with timolol or an alternative intraocular pressure\n             lowering medication such as trusopt, combigan, cosopt."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01927406", 
            "org_study_id": "26654"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Prostaglandin Analog vs Timolol", 
                    "Prostaglandin Analog"
                ], 
                "description": "The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.", 
                "intervention_name": "Prostaglandin Analog", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Bimatoprost", 
                    "Travoprost Z", 
                    "Tafluprost", 
                    "Latanoprost"
                ]
            }, 
            {
                "arm_group_label": "Prostaglandin Analog vs Timolol", 
                "description": "Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.", 
                "intervention_name": "Timolol", 
                "intervention_type": "Drug", 
                "other_name": "Timolol maleate 0.5%"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Timolol", 
                "Latanoprost", 
                "Travoprost", 
                "Bimatoprost"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Thyroid Eye Disease", 
            "Graves' Disease", 
            "Prostaglandin Analogues"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "location": {
            "contact": {
                "email": "bbartlet@stanford.edu", 
                "last_name": "Barbara Bartlett", 
                "phone": "650-724-9259"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94304"
                }, 
                "name": "Stanford Hospital and Clinics"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.", 
        "overall_contact": {
            "email": "bbartlet@stanford.edu", 
            "last_name": "Barbara Bartlett", 
            "phone": "650-724-9259"
        }, 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Andrea L. Kossler, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in appearance of facial periorbital region at 12 months.", 
            "safety_issue": "No", 
            "time_frame": "0 and 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01927406"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Andrea L Kossler", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in Hertel exophthalmometry at 12 and 24 months.", 
                "safety_issue": "No", 
                "time_frame": "0 and 24 months"
            }, 
            {
                "measure": "Change from baseline in intraocular pressure at 12 and 24 months.", 
                "safety_issue": "No", 
                "time_frame": "0 and 24 months"
            }, 
            {
                "measure": "Change from baseline in appearance of facial periorbital region at 24 months.", 
                "safety_issue": "No", 
                "time_frame": "0 and 24 months"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}